Using Dupixent and UVB therapy for treating atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a 24-week open-label study that investigates the effectiveness of dupilumab combined with narrowband UVB phototherapy for patients with moderate to severe atopic dermatitis. Participants will receive the combination treatment three times a week for the first 12 weeks, followed by 12 weeks of dupilumab alone. The study aims to assess the improvement in skin condition as measured by established clinical scores. The approach seeks to enhance treatment outcomes for individuals suffering from this chronic skin condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female adult ≥ 18 years of age;
* Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:

  * EASI score of 16 or greater,
  * IGA score of 3 or greater
  * BSA of 10% or greater,

Exclusion Criteria:

* Subjects with previous exposure to dupilumab.
* Known or suspected hypersensitivity to dupilumab or any of its excipients.
* History of photosensitivity.

Where it's running

• Eczema Treatment Center of New Jersey
  East Windsor, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Elise Nelson
• Email: enelson@windsordermatology.com
• Phone: 6094434500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if IBI3027 works as well as Dupilumab for moderate to severe atopic dermatitis

  This study tests whether IBI3027 can help people with moderate to severe atopic dermatitis as effectively as Dupilumab injections.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Guangzhou, Guangdong · NCT07754786

• Dupilumab's effect on anxiety and depression in moderate-to-severe atopic dermatitis

  This project will see if dupilumab reduces anxiety and depression in people with moderate-to-severe atopic dermatitis who are starting or recently started the medicine.

  Recruiting at 4 sites Sanofi · Doha and 6 other locations · NCT07467564

• Observing how adolescents with severe atopic dermatitis respond to dupilumab treatment

  This study looks at how well dupilumab treatment works for teenagers aged 12 to 17 with severe eczema over a year, focusing on their symptoms and quality of life.

  Recruiting at 9 sites Sanofi · Bologna and 8 other locations · NCT06192563

• Virtual reality game to reduce pain and anxiety during dupilumab injections

  This project will test whether a virtual reality game can reduce pain and anxiety for children aged 6–17 during dupilumab injections for moderate to severe atopic dermatitis.

  Recruiting at 2 sites St. Justine's Hospital · Montreal, Quebec and 1 other locations · NCT06182436

• Examining how dupilumab affects immune cells in atopic dermatitis

  This study is testing how the medication dupilumab affects immune cells in the skin of people with moderate to severe atopic dermatitis.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT05858619

• Exploring how dupilumab works differently in various ethnic groups with atopic dermatitis

  This study is testing how well dupilumab works for people with atopic dermatitis from different ethnic backgrounds, like Caucasian, Asian, and African American, to see if their responses vary.

  Recruiting Phase 4 University of Michigan · Ann Arbor, Michigan · NCT05268107

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.